IG
PGNX

ING Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

ING Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-200,000
Closed -$1.36M – 942
2017
Q2 		$1.36M Buy
+200,000
New +$1.48M 0.03% 262

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

ING Group's PGNX Position: Q3 2017 in Review

ING Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2017, closing a stake of 200,000 shares — an estimated $1.36M sold.

ING Group first reported a position in PGNX in Q2 2017 and held it in 1 quarter. The position peaked at $1.36M in Q2 2017. 142 funds tracked by Wall St. Rank hold PGNX as of Q3 2017.

  • ING Group reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • ING Group sold 200,000 Progenics Pharmaceuticals Inc shares in Q3 2017, an estimated $1.36M.
  • ING Group first reported a position in Progenics Pharmaceuticals Inc in Q2 2017 and held it in 1 quarter.
  • ING Group's Progenics Pharmaceuticals Inc position peaked at $1.36M in Q2 2017.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2017.

Based on ING Group's 13F filing for Q3 2017, filed 8 Nov 2017.